000			03017cam a2200313 a 4500
003			EG-GiCUC
008			210315s2020 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.08.M.Sc.2020.Ma.F
100	0		_aMaha Mohamed Abdullah Mahmoud
245	1	0	_aFormulation of nanocarriers for improvement of bioavailability of an antihypertensive drug : _bA pharmaceutical study / _cMaha Mohamed Abdullah Mahmoud ; Supervised Emad Basalious Besheir , Abeer Moustafa Khattab
246	1	5	_aصياغة حوامل متناهية الصغر لتحسين الحيوية لأحد العقاقير المضادة لارتفاع ضغط الدم : _bدراسة صيدلية
260			_aCairo : _bMaha Mohamed Abdullah Mahmoud , _c2020
300			_a109 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aAliskiren- hemifumarate (AF) is non-peptide direct renin inhibitor used as antihypertensive drug. Renin is secreted by kidney and cleaves its substrate, angiotensinogen, forming the inactive decapeptide (Ang I) that is converted to an active octapeptide (Ang II) by angiotensin converting enzyme (ACE). Ang II is a powerful vasoconstrictor, enhances catecholamine release from adrenal medulla, and promotes aldosterone secretion and sodium reabsorption. All the currently available agents that inhibit the renin system stimulate compensatory renin release from the kidney, which results in an increase in plasma renin activity (PRA) that may ultimately lead to increased levels of Ang II, So targeting the renin system at its point of activation by directly inhibiting renin activity has therefore long been proposed as the optimal means of suppressing the renin system. Despite its potency as antihypertensive drug, its bioavailability is very poor (about 2.5%) which explained by its high solubility and poor permeability. Aliskiren is administered in market in a dose 150-300 mg but for high drug cost, the amount of drug in the prepared formulations ranged from 25-50 mg. The goal of this thesis is to enhance oral bioavailability of aliskiren.The work is divided into three chapters as follows: Chapter I: Preparation and Characterization of Aliskiren- loaded Transferosomal Vesicles Chapter II: Preparation and Characterization of Aliskiren- loaded Self Nanoemulsifying System (SNES) Chapter III: Preparation and Characterization of a SNENVS Formulation and Bioequivalence Study of the SNENVS Formulation and the Marketed Tablet
530			_aIssued also as CD
653		4	_aBioavailability of an antihypertensive drug
653		4	_aNanocarriers for improvement
653		4	_aNngiotensin converting enzyme (ACE)
700	0		_aAbeer Moustafa Khattab , _eSupervisor
700	0		_aEmad Basalious Besheir , _eSupervisor
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c80264 _d80264